

TOTAL SYNTHESIS OF THE UNUSUAL CYCLOSPORINE AMINO ACID MeBMT

Roger D. Tung and Daniel H. Rich*
School of Pharmacy, University of Wisconsin-Madison
425 N. Charter St., Madison, WI 53706




Summary: Sharpless epoxidation of the readily available dienol **2**, followed by regiospecific opening with $\text{Me}_2\text{CuLi}/\text{BF}_3 \cdot \text{Et}_2\text{O}$ yields, after protecting group manipulation, the mono-protected diol **10c**. Swern oxidation gives the cyclic carbaminal **14a** which is easily manipulated to α -cyano oxazolidinone **15** and thus, by literature methods, to the title compound. Using this procedure, good overall yield and high enantiomeric purity are obtained.

In connection with our efforts to synthesize and elucidate the structure-activity relationships of the cyclosporines,^{1,2} we need large quantities of the unusual amino acid "MeBMT" (**1**). This β -OH α -amino acid, which appears necessary for full activity of the cyclosporines,^{2b} presents a synthetic challenge with its three contiguous asymmetric centers and trans-olefinic functionality. Two synthetic routes to **1** have been recently published;^{3,4} in this communication, we disclose preliminary results of a new route which can provide convenient access to **1** in large quantities.


Initially, we had envisaged "cutting into" Wenger's³ synthesis approximately half-way through his (twenty four step) route, by means of Sharpless epoxidation⁵ on the readily available^{6,7} dienol **2**, followed by regiospecific methylation with AlMe_3 ,^{8,9} thus setting the key stereochemistry at C2 (OH) and C3 (CH_3). Using compound **3a**¹⁰ as a model system, the desired diol was in fact produced in 80-90% yield as a single regioisomer.¹¹ However, when **3b** (from **2**: 2.2 eq. $^t\text{BuOOH}$, 0.08 eq. $\text{Ti}(\text{O}^i\text{Pr})_4$, 0.1 eq. L-DET, 5.5 h, 81%) was used, formation of a complex mixture occurred wherein the desired **5** was observed only as a minor product.

With direct methylation unavailable to us, we next attempted use of a bulky O-protecting group to effect regiospecificity in a cuprate opening. Introduction of the trityl ether, which appeared to be the protecting group of choice,¹² proceeded readily to yield **6** in 94% yield.¹³ To our initial dismay, however, a variety of lower and higher order, homo- and hetero- cuprates gave compounds **7** and **8** in ratios ranging from 1:1 to 1.5:1 favoring the undesired 1,3-diol derivative **7**. Useful ratios were finally obtained by the addition of $\text{BF}_3 \cdot \text{Et}_2\text{O}$,¹⁴ thus, 2 eq. each of Me_2CuLi and $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (Et_2O , -75° 20-30 min) yielded **7** and **8** in an 15:85 ratio with 94% conversion (**8**: $[\alpha]_D -15.4^\circ$, c 1.0, CHCl_3).

We had then planned to protect the C2 alcohol as a carbonate (**9a**), followed by C1 deprotection, oxidation to the aldehyde (**11a**), and a Strecker amino nitrile synthesis, analogous to that used by Wenger³. Intramolecular ring closure would then yield oxazolidinone **15**, which would be converted to MeBMT by the literature method. Reaction



a) 2.2 eq. ^tBuOOH, 0.08 eq. Ti(OⁱPr)₄, 0.1 eq. L-DET, -20°, 4 h, 81%; b) 1.1 eq. Ph₃CCl, 1.2 eq. DBU, 0° to room temp, 7 h, 94%; c) 2 eq. Me₂CuLi, 2 eq. BF₃·Et₂O, -75°C, 20-30 min, 14% 7, 80% 8; d)(to 9c) MeNCO, PhCH₃, 110° (sealed tube); e)(to 10a) 0.1 eq. ^pTsOH·H₂O, MeOH, 16 h, 64% from 8; f)(to 14a) 1.5 eq. (COCl)₂, 1.15 eq. DMSO, -40°, 15 min, then 5 eq. NEt₃; g)(to 14b) 1.25 eq. Ac₂O (in situ), room temp, 15 h, 83% from 10; h) 3 eq. TMSiCN, cat. BF₃·Et₂O, MeNO₂, 25 min, room temp, 97%; i) 2 eq. K₂CO₃, 95% EtOH, 9 h, room temp, 88%; j) 1.3 eq. HCl, 95% EtOH, 2.25 h, room temp, 72%.



of alcohol **8** with various chloroformates was poor, though, and furthermore the resultant carbonates cyclized to **12** upon C1 deprotection. Reaction of **8** with phenyl isocyanate to give **9b** was considerably more successful. However, deprotection and oxidation of the C1 alcohol gave the cyclic **13** (IR: 1745 cm^{-1} , NMR: H (C1) br m, δ 5.42 ppm) in good yield, rather than the expected open chain **11b**.¹⁵ At this point we realized that if conversion of the carbaminol hydroxyl to a carboxylate could be effected, this result might be highly useful, whereby the carbamate "protecting group" would act as the eventual progenitor of the desired methylamino functionality.


Accordingly, protection of **8** as the methyl carbamate (**9c**; mp 125-127.5° from cyclohexane; $[\alpha]_{\text{D}} +6.5^\circ$, c 1.0, EtOH) was carried out, followed by removal of the trityl group, to yield **10c** (mp 60.5-62° from cyclohexane; $[\alpha]_{\text{D}} +31.5^\circ$, c 1.0, CHCl_3) in 64% overall yield. Swern oxidation¹⁶ followed by *in situ* acetylation (1.25 eq. Ac_2O , 16 h at room temp.), then gave the oily acetate **14b** as a ca. 1:1 mixture of diastereomers in 83% yield from **10c**.¹⁷ Reaction of **14b** with TMSCN in the presence of catalytic $\text{BF}_3 \cdot \text{Et}_2\text{O}$ in nitromethane¹⁸ gave the desired **15** as a ca. 1.6:1 ratio of cis:trans isomers (relative to the oxazolidinone ring) in excellent yield.¹⁹ Compound **4** was converted to the carboethoxy oxazolidinone **16** by the literature method.^{3,20} The optical rotation of the material thus obtained ($[\alpha]_{\text{D}} +27.6^\circ$, c 1.0, CHCl_3 vs. lit.³ $[\alpha]_{\text{D}} +29.5^\circ$, c 1.0, CHCl_3) indicated an e.e. of 94%, which should be suitable for virtually all uses. Enantiomerically pure material is obtained, if desired, by conversion to the free acid and crystallization with (+)-ephedrine.²¹

This synthetic route provides a convenient method for obtaining MeBMT in quantity, with a minimum of steps requiring chromatographic purification. Full experimental details for scaleup to multigram quantities and applications to the synthesis of novel analogs of **1** will be reported in due course.

References

- 1a) Tung, R. D.; Dhaon, D. K.; and Rich, D. H. *J. Org. Chem.* **51**: 3350-54 (1986) b) Rich, D. H.; Dhaon, M. K.; Dunlap, B.; and Miller, S. P. F. *J. Med. Chem.* **29**: 978-84 (1986).
- 2a) Borel, J. F. in "Cyclosporine A"; White, D. J. G., Ed. Elsevier Biomedical, Amsterdam: 1982; pp. 5-17. b) Wenger, R. M. *Prog. Allergy* **38**: 46-64 (1986).
- 3) Wenger, R. M. *Helv. Chim. Acta* **66**: 2308-21 (1983).
- 4) Evans, D. A. and Weber, A. E. *J. Am. Chem. Soc.* **108**: 6757-61 (1986).
- 5a) Katsuki, T. and Sharpless, K. B. *J. Am. Chem. Soc.* **102**: 5974-6 (1980) b) Hanson, R. M. and Sharpless, K. B. *J. Org. Chem.* **51**: 1922-5 (1986).
- 6) Chin, S.K.; Golding, B. T.; and Pierpoint, C. *J. Chem. Res. (M)* (1985) 0946-0953.
- 7) In earlier runs, a persistent impurity later identified as the 1,4-addition product of propargyl alcohol dianion to the crotyl bromide was carried through the first several steps. This regioisomer was removed at the stage of ring opening (**9** to **10**). Isomerically pure **6** may be obtained by more careful distillation of the precursor ynol (c.f. ref. 7); however our currently preferred approach is to carry the mixture of compounds through to the stage of methyl carbamate **10b**, then purify it by recrystallization.
- 8) Suzuki, I; Saimoto, H.; Tomioka, H.; Oshima, K.; and Nozaki, H. *Tetrahedron Lett.* **23**: 3597-600 (1982).
- 9) All compounds were characterized by high field (200 or 270 MHz) ^1H NMR, LR-MS, and TLC in two or more systems.

- 10) Pickenhagen, W. and Broenner-Schindler, H. *Helv. Chim. Acta* **67**: 947-52 (1984).
 b) Gorthey, L. A.; Vairamani, M.; and Djerassi, C. *J. Org. Chem.* **49**: 1511-17 (1984).
 11) We have found that, in contrast to the literature method, material of higher yield and regiochemical purity is obtained by treatment of the substrate as a hexanes solution with the AlMe_3 reagent.
 12) Kobayashi, Y.; Kitano, Y.; and Sato, F. *J. Chem. Soc. Chem. Commun.* (1984) 1329-30.
 13) Adapted from a procedure for the introduction of the TBS group: Aizpura, J. M. and Palomo, C. *Tetrahedron Lett.* **26**: 475-6 (1985).
 14) Compare: Eis, M. J.; Wrobel, J. E.; and Ganem, B. *J. Am. Chem. Soc.* **106**: 3693-4 (1984). In this instance, use of $\text{MeLi}/\text{BF}_3 \cdot \text{Et}_2\text{O}$ failed to produce ring opening.
 15) In retrospect, this result might have been anticipated. The reaction of amides and carbamates with aldehydes to give alkylols is well documented (see Freidinger, R. M.; Hinkle, J. S.; Perlow, D. S.; and Arison, B. H. *J. Org. Chem.* **48**: 77-81 (1983) and references therein). Another case of intramolecular carbaminol closure has also been noted in our laboratory: see Salituro, F. G. Ph.D. dissertation, Univ. of Wisconsin-Madison, pp. 48-49 (1984).
 16) Mancuso, A. J.; Huang, S.-L.; and Swern, D. *J. Org. Chem.* **43**: 2480-2 (1978).
 17) Interestingly, attempted displacement of the acetate with TMSCN (1.3 eq.) and TiCl_4 (1.1 eq.) in CH_2Cl_2 (-75 to 10°, 16h) Renaud, von P. and Seebach, D. *Angew. Chem.* **98**: 836-8 (1986) gave the bicyclic oxazolidinone **17** as the major product.
 18) de la Heras, F. G. and Fernandez-Resa, P. *J. Chem. Soc. Perkin I* 903-7 (1982).
 19) Direct conversion of **11** to **13** was possible by this method; however, yields were considerably lower (ca. 20%).
 20) In our hands, complete epimerization to the desired "trans" (4S, 5R) oxazolidinone does not take place under the literature conditions, a ca. 8:1 ratio of (easily separated) trans:cis being obtained instead. We are currently exploring methods for obtaining the "trans" compound exclusively.
 21) Aebi, J. and Rich, D. H. Unpublished observations.



Acknowledgements: This work was supported in part by NIH grant AM32007. We would like to thank Professors H. J. Reich and K. B. Sharpless for helpful discussions, and Professor D. A. Evans and Ann Weber for providing us with data prior to publication of reference 4.

(Received in USA 10 December 1986)